" class="no-js "lang="en-US"> Tedros Adhanom Ghebreyesus - Medtech Alert
Tuesday, September 30, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Tedros Adhanom Ghebreyesus

Tedros Adhanom Ghebreyesus

About Tedros Adhanom Ghebreyesus

I envision a world in which everyone can live healthy, productive lives, regardless of who they are or where they live.

Related Story

Diseases

 BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa | Pharmtech Focus

BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa

June 24 2022

BioNTech SE (Nasdaq: BNTX, “BioNTech”) has reached the next milestone in the establishment of scalable mRNA […]

Diseases

 WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk | Pharmtech Focus

WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk

October 7 2021

The World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine […]